论文信息 - Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. - 字舞流文

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

A. LaCasce | S. Tyekucheva | M. Davids | D. Fisher | C. Jacobson | S. Ng | Jennifer R. Brown | M. Weinstock | J. Arnason | P. Armand | B. Lampson | Jennifer L. Crombie | Austin I. Kim | Zixu Wang | Jessica C Lowney | S. Pazienza | Josie S. Montegaard | V. Patterson | J. Crombie | J. Montegaard | A. Kim | Philippe Armand